Gsk (GLAXF) Receivables - Net (2009 - 2026)

Gsk's Receivables - Net history runs 18 years deep, the most recent figure standing at $10.5 billion for Q1 2026.

• In Q1 2026, Receivables - Net rose 17.61% year-over-year to $10.5 billion; the TTM figure through Mar 2026 stood at $10.5 billion (up 17.61% YoY), while the FY2025 annual figure was $9.9 billion, up 12.73% from the prior year.
• Receivables - Net was $10.5 billion for Q1 2026 at Gsk, up from $9.9 billion in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $10.8 billion in Q3 2023 to a low of $3.2 billion in Q1 2022.
• Historically, Receivables - Net has averaged $8.9 billion across 5 years, with a median of $8.9 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net plunged 63.8% in 2022, then soared 156.3% in 2023.
• A 5-year view of Receivables - Net shows it stood at $8.3 billion in 2022, then increased by 10.8% to $9.2 billion in 2023, then slipped by 4.28% to $8.8 billion in 2024, then climbed by 13.26% to $9.9 billion in 2025, then advanced by 5.22% to $10.5 billion in 2026.
• The last three Receivables - Net figures came in at $10.5 billion (Q1 2026), $9.9 billion (Q4 2025), and $10.7 billion (Q3 2025), per Business Quant data.